🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Agenus Inc. AGEN PHARMA

Healthcare · Biotechnology · United States
https://www.agenusbio.com
Company Profile ↓
$7.43
+63.66% 1Y
Mkt Cap$334.50M
P/E2.48
P/B-1.47
52W High$8.36
52W Low$2.77
Book Value$-4.67
EPS (TTM)$2.99

Company Overview

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 21.3%.

Steady Revenue Expansion

Revenue has grown at a 26.6% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 2.5, below the sector median of 24.8.

Healthy Margins

Maintains a net profit margin of 69.3%.

Recent Developments

  • Dec 2025 Revenue of $114.20M (+10.4% YoY); net profit $115.00K.
  • Trailing 12 Months Year-on-year growth — revenue +34.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR 26.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:26.56%
1 Year:34.40%

Stock Price Performance

1 Year:+63.66%
6 Months:+135.87%
3 Months:+136.62%
1 Month:+6.75%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 83% of range
$2.77 $8.36
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)50.27 · Neutral
Price Performance
1M+6.75%
3M+136.62%
6M+135.87%
1Y+63.66%
Valuation vs Sector

P/E of 2.48 is below the sector median of 24.83 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 21.3%.
  • Excellent profit margin of 69.3%.
  • Compounding revenue at 26.6% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
2.48
Industry PE
24.83
Forward P/E
-123.83
PEG Ratio
1.44
Book Value
$-4.67
Price to Book
-1.47
P/S
2.33
EV/EBITDA
8.61
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
26.56%
Profit 5Y
-
Revenue (YoY)
34.40%
Earnings (YoY)
-

Profitability & Returns

ROCE
21.26%
ROE
-0.04%
ROA
12.53%
Profit Margin
69.34%
Op Margin
32.72%
Gross Margin
-
EPS (Latest Qtr)
$-0.01
EPS (TTM)
$2.99

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
0.32
Current Ratio
0.34
Debt
$40.71M
Total Assets
$172.69M
Current Assets
$95.28M
Working Capital
$-190.05M

Ownership

Promoter Holding
6.24%
Chg in Prom Hold
0.01%
FII / Inst Holding
46.38%
Chg in FII Hold
0.02%

Financial Snapshot

Enterprise Value
$334.50M
Total Revenue (TTM)
$132.69M
EBITDA
$40.61M
Free Cash Flow
$-74.79M
Operating Cash Flow
$-98.50M
Shares Outstanding
45.02M
Gross Margin
-
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 AGEN Agenus Inc. PHARMA 7.43 2.48 $334.50M 0.00% 21.26% -0.04% 26.56% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue ------26.96M4.21M3.36M8.35M1.64M15.89M12.80M6.45M79.89M15.71M19.94M34.50M15.13M26.95M14.83M31.27M11.72M10.73M252.95M25.94M20.93M22.77M22.90M25.30M24.31M28.00M23.51M25.11M24.07M25.69M30.23M34.20M33.74M34.52M
Cost of Revenue ----------------------------------21.66M26.95M24.24M7.51M11.82M-
Gross Profit ----------------------------------2.41M-1.26M6.00M26.69M21.91M-
Operating Expenses ----------------------------------15.72M15.52M10.86M12.29M6.86M-
Operating Income -11.07M--27.97M-23.61M-36.22M--13.26M-28.89M-31.66M--41.75M-16.57M-26.07M-26.21M-41.15M-35.92M--27.46M-33.27M-34.79M--41.37M-66.39M187.54M-35.46M-44.56M-41.65M-54.34M-54.67M-46.34M-32.88M-30.19M-31.50M-13.31M-16.78M-4.86M14.40M15.05M11.29M
EBITDA -----------------------------------10.37M-13.55M80.11M6.00M54.46M-
Interest Expense ----------------------------------12.79M13.29M13.17M16.02M14.67M-
Pretax Income -----------------------------------26.37M-30.01M63.91M-10.61M39.21M-
Tax Provision ----------------------------------------
Net Income -13.12M-15.61M-31.78M-28.32M-40.77M-26.12M-17.10M-31.71M-36.84M-35.03M-54.26M-25.20M-33.73M-48.85M17.43M-51.87M-46.28M-30.85M-45.27M-48.24M-51.65M-37.73M-------------25.27M-27.95M63.91M-10.58M39.23M-
Diluted EPS -----------0.53---0.12-0.38-0.33-0.22-0.31--0.28---0.370.72-0.19-0.17-0.19-4.31-3.93-3.29-3.04-2.52-3.08-1.03-1.001.94-1.02-0.01
R&D Expense 18.50M-25.04M22.36M21.59M-32.64M25.82M25.79M-29.44M29.27M29.85M-40.13M45.24M46.13M-36.36M38.55M32.13M-36.68M45.51M42.94M42.44M44.96M46.01M57.12M59.28M51.44M43.92M36.77M41.06M21.52M26.71M23.60M-11.82M14.76M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 3.33M3.36M2.76M15.96M3.05M6.98M24.82M22.57M42.88M36.78M150.05M88.17M-98.02M156.31M103.46M114.20M
Cost of Revenue -------------197.26M237.68M156.01M80.36M
Gross Profit --------------99.23M-81.37M-52.55M33.84M
Operating Expenses -------------81.01M78.74M71.88M54.39M
Operating Income -27.68M-21.75M-19.09M-6.74M-24.98M-43.32M-80.70M-107.48M-103.80M-123.82M-70.14M-117.23M--180.24M-160.10M-124.43M-20.56M
EBITDA --------------161.85M-145.92M-101.30M62.19M
Interest Expense -------------61.86M97.92M117.63M55.27M
Pretax Income --------------230.66M-257.44M-232.27M-3.08M
Tax Provision -----------------
Net Income -30.32M-21.91M-23.28M-11.32M-30.07M-42.49M-87.88M-127.00M-120.69M-159.90M-107.86M-181.12M--220.07M-245.76M-227.21M115.00K
Diluted EPS ------------1.05--15.64-13.75-10.590.00
R&D Expense 16.90M12.88M11.02M10.56M13.01M22.35M70.44M94.97M116.12M124.60M168.34M142.62M178.61M186.69M234.57M155.53M79.34M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Jan 2018Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --30.91M19.81M29.09M34.84M74.53M242.23M---156.99M---138.40M-136.40M155.34M214.51M-413.56M313.91M226.27M226.80M
Current Assets ---------------------213.12M112.42M45.57M133.44M
Cash & Equivalents 24.47M20.07M19.78M10.75M21.47M27.35M25.71M136.70M148.20M123.30M95.40M71.45M123.80M96.80M70.10M60.19M86.80M53.05M61.81M99.87M-178.67M76.11M40.44M3.00M
Inventory -------------------------
Receivables ---------------------2.74M25.84M407.00K1.83M
Total Liabilities ---------------------468.46M462.30M532.70M504.66M
Current Liabilities --5.42M4.75M4.81M10.30M9.23M28.93M---40.85M---56.44M-68.06M122.21M129.88M-188.95M255.90M221.40M323.49M
Long Term Debt ------4.77M114.33M---130.54M---142.39M-13.21M13.38M18.88M12.82M12.58M12.77M30.47M-
Total Debt ---------------------78.43M88.47M94.87M55.90M
Total Equity -20.33M-16.97M-14.71M-20.83M-17.60M-4.48M23.02M70.73M----39.13M----75.82M--172.47M-225.36M-203.67M--61.28M-160.33M-326.38M-271.11M
Shares Outstanding ---------------------15.28M19.72M23.63M35.32M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -24.19M-14.76M-16.25M1.01M-19.53M-38.23M--79.96M-94.23M-131.09M-18.68M-139.10M--175.37M-224.20M-158.31M-77.19M
Investing Cash Flow 2.16M9.93M-29.46K-103.44K-363.52K-16.81M-17.60M2.06M-3.59M-4.66M-4.44M--33.61M3.40M27.00K1.19M
Financing Cash Flow 17.63M4.54M7.24M9.81M25.78M52.81M--2.46M80.54M128.29M31.32M183.85M-95.83M119.87M122.84M36.59M
Capital Expenditure -243.87K-130.44K-54.55K-103.44K-813.52K-2.82M-3.59M-12.52M-3.12M-3.60M-4.66M-3.47M--53.06M-9.95M-576.00K-6.00K
Free Cash Flow -24.44M-14.89M-16.30M909.16K-20.35M-41.05M--92.48M-97.35M-134.69M-23.34M-142.56M--228.44M-234.16M-158.89M-77.20M
Net Change in Cash --------------113.15M-100.94M-35.45M-39.41M
Share Buybacks 54.94K00--------------

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % --------------101.2%-52.1%-50.8%29.6%
Operating Margin % -830.1%-647.5%-692.6%-42.2%-820.3%-620.9%-325.2%-476.1%-242.1%-336.6%-46.7%-133.0%--183.9%-102.4%-120.3%-18.0%
Net Margin % -909.2%-652.0%-844.6%-71.0%-987.5%-608.9%-354.1%-562.6%-281.5%-434.7%-71.9%-205.4%--224.5%-157.2%-219.6%0.1%
ROE % 178.6%148.9%111.7%64.3%671.2%-184.6%-124.3%324.6%159.2%92.7%47.9%88.9%-359.1%153.3%69.6%-0.0%
ROCE % --85.3%-126.8%-27.8%-101.8%-66.3%-37.8%-92.5%-126.6%-181.2%-211.7%-138.5%--80.2%-276.0%-2,555.0%21.3%

Shareholding Pattern

Insiders
6.24%
Institutions
46.38%
Public Float
49.46%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 5.68% 2.56M $20.13M
2 Vanguard Capital Management LLC 3.71% 1.68M $13.16M
3 Vanguard Portfolio Management LLC 3.16% 1.43M $11.21M
4 Siren, L.L.C. 2.36% 1.06M $8.35M
5 Geode Capital Management, LLC 2.29% 1.04M $8.13M
6 Mackenzie Financial Corporation 1.58% 714.17K $5.61M
7 Goldman Sachs Group Inc 0.99% 448.38K $3.52M
8 Marshall Wace LLP 0.97% 439.62K $3.45M
9 Raymond James Financial, Inc. 0.95% 430.08K $3.38M
10 Globeflex Capital L P 0.93% 418.58K $3.29M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AGEN

Yahoo Finance Mon, 31 Aug 2026

Agenus to Participate in Upcoming September Investor Conferences

LEXINGTON, Mass., August 31, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Ph.D., Chief Commercial Officer, and Zack Armen, Head of Corporate Development and Investor Relations,…

Yahoo Finance Fri, 28 Aug 2026

Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

LEXINGTON, Mass., August 28, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of mature Phase 1b results from the fully enrolled C-800-01 cohort evaluating botensilimab …

Yahoo Finance Wed, 26 Aug 2026

Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer

LEXINGTON, Mass., August 26, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of updated results from the investigator-sponsored Phase 2 NEST trial evaluating neoadjuvan…

Yahoo Finance Sun, 16 Aug 2026

Agenus (AGEN) Stock Fair Value Falls After Analysts Rework Pipeline And Financing Assumptions

The latest analyst update on Agenus centers on a reset of its fair value estimate, with the price target moving from US$30.00 to US$19.50. This change reflects recent Street research that balances optimism about the refocused botensilimab a…

Yahoo Finance Fri, 07 Aug 2026

Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of -120.00% and +1.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Yahoo Finance Fri, 17 Jul 2026

Agenus (AGEN) Could Be 83% Undervalued Following Phase 1b Data And Financing

Agenus (AGEN) is back in focus after reporting three year Phase 1b data for its BOT+BAL immunotherapy in refractory microsatellite stable metastatic colorectal cancer, alongside an oversubscribed private placement tied to its registrational…

AGEN — Frequently Asked Questions

What is the current share price of Agenus Inc. (AGEN)?

As of 2026-09-19 21:16 PDT, Agenus Inc. (AGEN) trades at $7.43 on NasdaqCM. Its 52-week range is $2.77 to $8.36.

What is the market capitalisation of AGEN?

Agenus Inc. (AGEN) has a market capitalisation of $334.50M on NasdaqCM.

What is the P/E ratio of AGEN?

AGEN trades at a trailing price-to-earnings (P/E) ratio of 2.48. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -1.47.

What is the return on equity (ROE) of AGEN?

AGEN has a return on equity (ROE) of -0.04%. Its return on capital employed (ROCE) is 21.26%.

Is AGEN a good stock to buy?

This page provides a data-driven analysis of Agenus Inc. (AGEN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space